Publications by authors named "Christian Grohe"

Claim this Profile
M
Mycobacterium florentinum pulmonary disease: a case report and review of the literature.
Fabian Leo, Silke Polsfuss, Anne-Sophie Przewosnik, Christian Grohé, Christoph Lange

BMC Infect Dis· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line nivolumab plus ipilimumab in pleural mesothelioma: Efficacy and safety data from the real-world MesoNet study.
Rajiv Shah, Eva L Buchmeier, Hans-Georg Kopp, Daniel C Christoph, Frank Griesinger

Lung Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.
Amin H Nassar, Chul Kim, Tolulope Adeyelu, Elias Bou Farhat, Hassan Abushukair, Christian Grohe

Nat Commun· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Real-World Evaluation of Brain Imaging in Patients with Advanced Non-Small Cell Lung Cancer: Insights from a German Claims Data Analysis.
Akin Atmaca, Christian Grohé, Moritz Klinghardt, Nils Kossack, Marc Pignot

Oncol Res Treat· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).
Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, Marc Bischof, Akin Atmaca, Christian Grohe

Clin Exp Metastasis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
Roy S Herbst, Thomas John, Christian Grohé, Jonathan W Goldman, Terufumi Kato

Nat Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
Luis Paz-Ares, Hossein Borghaei, Stephen V Liu, Solange Peters, Roy S Herbst

Lancet· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life characteristics and management of patients with fibrosing interstitial lung disease: INSIGHTS-ILD registry.
Jürgen Behr, Michael Kreuter, Andreas U Guenther, Francesco Bonella, David Pittrow

ERJ Open Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glucocorticoid-Induced Adrenal Insufficiency in Sarcoidosis Patients with Long-term Glucocorticoid Therapy.
Roman Düvel, Vanessa Marggraf, Carmen Pizarro, Leonie Biener, Wiebke Fenske

Pneumologie· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study.
Claus von Hessert-Vaudoncourt, Sebastian Maasberg, Nehara Begum, Anja Rinke, Thorsten Pöppel, Christian Grohe

Medicine (Baltimore)· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLC.
Amin H Nassar, Ritujith Jayakrishnan, Jamie Feng, Frances Shepherd, Elio Adib, Christian Grohe

J Thorac Oncol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy.
Felix Carl Saalfeld, Johanna Möller, Petros Christopoulos, Carina Wenzel, Anna Rasokat

Eur J Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Parsonage-Turner-syndrome associated with infection.
Fabian Leo, Christian Grohé

Respirol Case Rep· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations" [Eur J Cancer 199 (2024) 113556].
Miriam Blasi, Jonas Kuon, Heike Lüders, Daniel Misch, Diego Kauffmann-Guerrero

Eur J Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.
Amin H Nassar, So Yeon Kim, Jacqueline V Aredo, Jamie Feng, Frances Shepherd, Christian Grohe

J Thorac Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany.
Jan A Stratmann, Friederike C Althoff, Paula Doebel, Jacqueline Rauh, Arne Trummer

Eur J Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical course of mild-to-moderate idiopathic pulmonary fibrosis during therapy with pirfenidone: Results of the non-interventional study AERplus.
Jens Schreiber, Wolfgang Schütte, Wolfgang Koerber, Bernd Seese, Dirk Koschel

Pneumologie· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations.
Miriam Blasi, Jonas Kuon, Heike Lüders, Daniel Misch, Diego Kauffmann-Guerrero

Eur J Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Therapeutic Pathways in Sarcoidosis. A Position Paper of the German Society of Respiratory Medicine (DGP)].
Dirk Skowasch, Francesco Bonella, Katharina Buschulte, Nikolaus Kneidinger, Peter Korsten

Pneumologie· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Masahiro Tsuboi, Roy S Herbst, Thomas John, Terufumi Kato, Margarita Majem

Target Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolutionary trajectories of small cell lung cancer under therapy.
Julie George, Lukas Maas, Nima Abedpour, Maria Cartolano, Laura Kaiser

Nature· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lurbinectedin in patients with small cell lung cancer with chemotherapy-free interval ≥30 days and without central nervous metastases.
Solange Peters, José Trigo, Benjamin Besse, Victor Moreno, Alejandro Navarro

Lung Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TTF-1 status in early-stage lung adenocarcinoma is an independent predictor of relapse and survival superior to tumor grading.
Simon Schallenberg, Gabriel Dernbach, Mihnea P Dragomir, Georg Schlachtenberger, Kyrill Boschung

Eur J Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report.
Myriam Mirza, Aseem Shrivastava, Cecile Matthews, Natasha Leighl, Calvin S H Ng, Christian Grohe

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Medication treatment in pulmonary arterial hypertension with comorbidities - Which phenotypes and points to consider].
Ekkehard Grünig, Michael Halank, Claus Neurohr, Jürgen Behr, Katrin Milger-Kneidinger

Pneumologie· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis